Exp Clin Endocrinol Diabetes 2010; 118(1): 4-8
DOI: 10.1055/s-0029-1243193
Mini-Review

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Diabetes Mellitus Type 2 – An Independent Risk Factor for Cancer?

V. A. Grote1 , S. Becker1 , R. Kaaks1
  • 1Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Further Information

Publication History

received 11.11.2009 first decision 11.11.2009

accepted 11.11.2009

Publication Date:
01 February 2010 (online)

Abstract

Epidemiological findings have shown up to two-fold increases in the risks of cancers of the colorectum, breast, endometrium, kidney (renal cell tumours), liver and pancreas among diabetes patients. In the present review, we address the question whether, on the basis of these epidemiological observations, type 2 diabetes should be considered a specific and independent risk factor for these various forms of cancer, due to its particular metabolic characteristics of glucose intolerance and hyperinsulinemia. On the basis of further epidemiological evidence among non-diabetic individuals, as well as recent studies examining the effects of different types of diabetes treatment on cancer risks, we conclude that chronic elevations in fasting and non-fasting blood levels of glucose and/or insulin are plausible independent risk factors for cancer, but that much of the increase in cancer risks associated with these two metabolic factors may occur within the normoglycaemic and insulinemic (non-diabetic) ranges. Furthermore, for some tumour types (e. g. cancer of the endometrium) the associations of risk with type 2 diabetes may to a large extent be due to, and at least partially confounded by, other obesity-related alterations in (e. g. sex steroid) metabolism that in part are independent of glucose and/or insulin metabolism. Specifically for pancreatic cancer, a major question, addressed in detail by other reviews, is whether associations of risk with plasma glucose, insulin or overt type 2 diabetes could be either a cause, or possibly also a consequence of tumour development (or both).

References

  • 1 Anderson KE, Anderson E. et al . Diabetes and endometrial cancer in the Iowa women's health study.  Cancer Epidemiol Biomarkers Prev. 2001;  10 611-616
  • 2 Becker S, Dossus L. et al . Obesity related hyperinsulinaemia and hyperglycaemia and cancer development.  Arch Physiol Biochem. 2009;  115 86-96
  • 3 Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.  Nat Rev Cancer. 2004;  4 579-591
  • 4 Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.  Diabetologia. 2009;  52 1755-1765
  • 5 Cust AE, Kaaks R. et al . Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).  Endocr Relat Cancer. 2007;  14 755-767
  • 6 Frasca F, Pandini G. et al . The role of insulin receptors and IGF-I receptors in cancer and other diseases.  Arch Physiol Biochem. 2008;  114 23-37
  • 7 Friberg E, Orsini N. et al . Diabetes mellitus and risk of endometrial cancer: a meta-analysis.  Diabetologia. 2007;  50 1365-1374
  • 8 Gapstur SM, Gann PH. et al . Abnormal glucose metabolism and pancreatic cancer mortality.  JAMA. 2000;  283 2552-2558
  • 9 Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer.  Horm Metab Res. 2003;  35 694-704
  • 10 Hemkens LG, Grouven U. et al . Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.  Diabetologia. 2009;  52 1732-1744
  • 11 Huxley R, Ansary-Moghaddam A. et al . Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies.  Br J Cancer. 2005;  92 2076-2083
  • 12 IDF .(November 4th 2009). “Diabetes Atlas” 2009, from http://www.eatlas.idf.org/atlasff5d.html?id=0.
  • 13 Inoue M, Iwasaki M. et al . Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan.  Arch Intern Med. 2006;  166 1871-1877
  • 14 Jee SH, Ohrr H. et al . Fasting serum glucose level and cancer risk in Korean men and women.  JAMA. 2005;  293 194-202
  • 15 Jonasson JM, Ljung R. et al . Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.  Diabetologia. 2009;  52 1745-1754
  • 16 Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I.  Proc Nutr Soc. 2001;  60 91-106
  • 17 Kaaks R, Lukanova A. et al . Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review.  Cancer Epidemiol Biomarkers Prev. 2002;  11 1531-1543
  • 18 Kabat GC, Kim M. et al . Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer.  Int J Cancer. 2009;  125 2704-2710
  • 19 Kahn SE, Hull RL. et al . Mechanisms linking obesity to insulin resistance and type 2 diabetes.  Nature. 2006;  444 840-846
  • 20 Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer.  Cancer Epidemiol Biomarkers Prev. 2006;  15 2056-2062
  • 21 Kolonel LN, Altshuler D. et al . The multiethnic cohort study: exploring genes, lifestyle and cancer risk.  Nat Rev Cancer. 2004;  4 519-527
  • 22 Larsson SC, Mantzoros CS. et al . Diabetes mellitus and risk of breast cancer: a meta-analysis.  Int J Cancer. 2007;  121 856-862
  • 23 Larsson SC, Orsini N. et al . Diabetes mellitus and risk of colorectal cancer: a meta-analysis.  J Natl Cancer Inst. 2005;  97 1679-1687
  • 24 Leitzmann MF, Ahn J. et al . Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.  Cancer Causes Control. 2008;  19 1267-1276
  • 25 Libby G, Donnelly LA. et al . New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.  Diabetes Care. 2009;  32 1620-1625
  • 26 Luo Z, Saha AK. et al . AMPK, the metabolic syndrome and cancer.  Trends Pharmacol Sci. 2005;  26 69-76
  • 27 Mayer D, Shukla A. et al . Proliferative effects of insulin analogues on mammary epithelial cells.  Arch Physiol Biochem. 2008;  114 38-44
  • 28 Mink PJ, Shahar E. et al . Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study.  Am J Epidemiol. 2002;  156 349-352
  • 29 Mori M, Saitoh S. et al . A Review of Cohort Studies on the Association Between History of Diabetes Mellitus and Occurrence of Cancer.  Asian Pac J Cancer Prev. 2000;  1 269-276
  • 30 Muti P, Quattrin T. et al . Fasting glucose is a risk factor for breast cancer: a prospective study.  Cancer Epidemiol Biomarkers Prev. 2002;  11 1361-1368
  • 31 Pannala R, Basu A. et al . New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer.  Lancet Oncol. 2009;  10 88-95
  • 32 Parkin DM, Bray F. et al . Global cancer statistics, 2002.  CA Cancer J Clin. 2005;  55 74-108
  • 33 Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies.  Arch Physiol Biochem. 2008;  114 63-70
  • 34 Pollak M. Insulin and insulin-like growth factor signalling in neoplasia.  Nat Rev Cancer. 2008;  8 915-928
  • 35 Rapp K, Schroeder J. et al . Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria.  Diabetologia. 2006;  49 945-952
  • 36 Rinaldi S, Rohrmann S. et al . Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European prospective investigation into cancer and nutrition.  Cancer Epidemiol Biomarkers Prev. 2008;  17 3108-3115
  • 37 Rodriguez C, Patel AV. et al . Diabetes and risk of prostate cancer in a prospective cohort of US men.  Am J Epidemiol. 2005;  161 147-152
  • 38 Stattin P, Bjor O. et al . Prospective study of hyperglycemia and cancer risk.  Diabetes Care. 2007;  30 561-567
  • 39 Stocks T, Lukanova A. et al . Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden.  Int J Cancer. 2007;  120 2678-2686
  • 40 Stolzenberg-Solomon RZ, Graubard BI. et al . Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers.  JAMA. 2005;  294 2872-2878
  • 41 Stumvoll M, Goldstein BJ. et al . Type 2 diabetes: principles of pathogenesis and therapy.  Lancet. 2005;  365 1333-1346
  • 42 Wang F, Herrington M. et al . The relationship between diabetes and pancreatic cancer.  Mol Cancer. 2003;  2 4
  • 43 WHO . (November 4th 2009). “Diabetes Facts & Figures”. 2009, from  http://www.who.int/diabetes/facts/world_figures/en/index.html.

Correspondence

R. Kaaks

Division of Cancer

Epidemiology Deutsches Krebsforschungszentrum

Im Neuenheimer Feld 280

69120 Heidelberg

Germany

Phone: +49 6221 422 202

Fax: +49 6221 42 22 03

Email: r.kaaks@dkfz.de

    >